26 Sep 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250926821731/en/Enanta-Pharmaceuticals-to-Present-Topline-Results-from-its-Phase-2b-Study-Evaluating-Zelicapavir-for-the-Treatment-of-Respiratory-Syncytial-Virus-RSV-in-High-Risk-Adults
22 May 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250522937132/en/Enanta-Pharmaceuticals-Announces-Data-from-its-Phase-2-Study-of-Zelicapavir-in-Children-with-Respiratory-Syncytial-Virus-to-be-Presented-at-the-43rd-Annual-ESPID-Meeting